Is SEPN a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on The Novo Nordisk collaboration, with revenue (ttm) at ~$99 million, essentially all collaboration revenue from Novo Nordisk rather than product sales. The bear case rests on every clinical-stage biotech carries binary risk, and here it has already been demonstrated: SEP-786 was discontinued in February 2025 after two severe cases of elevated unconjugated bilirubin, and the stock fell 47% that day. Analysts covering it are spread from $38.00 to $60.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Every clinical-stage biotech carries binary risk, and here it has already been demonstrated: SEP-786 was discontinued in February 2025 after two severe cases of elevated unconjugated bilirubin, and the stock fell 47% that day. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $38.00, -20.4% from the $47.76 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

The Novo Nordisk collaboration. The partnership covers oral small molecule programs against specified GPCR targets in obesity, type 2 diabetes and related cardiometabolic disease, and it is the source of nearly all reported revenue. The most optimistic analyst target on SEPN is $60.00, +25.6% from the $47.76 price. That figure is only reachable if this thesis works close to its best case.

Every clinical-stage biotech carries binary risk, and here it has already been demonstrated: SEP-786 was discontinued in February 2025 after two severe cases of elevated unconjugated bilirubin, and the stock fell 47% that day. Several plaintiffs' firms announced investigations in the weeks after, which is a routine response to a drop of that size and did not produce a widely reported class action, but the episode is the clearest illustration of how this name trades on single data points. Revenue is collaboration accounting rather than product sales, so it is not a floor under the valuation, and Novo Nordisk can deprioritize programs. With roughly 46.7 million shares outstanding the float is small and daily moves of 20% in either direction are ordinary. Both target markets are contested, hypoparathyroidism by Ascendis and AstraZeneca with approved or late-stage injectables and chronic spontaneous urticaria by several biologics and oral candidates, so positive data still has to clear a commercial bar rather than an empty field. The most pessimistic published target is $38.00, -20.4% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Clinical-stage biotech developing oral small molecules against GPCR targets, funded by a Novo Nordisk cardiometabolic collaboration.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The Novo Nordisk collaboration) stalling in the reported numbers rather than in the narrative, the risk above (every clinical-stage biotech carries binary risk, and here it has already been demonstrated: SEP-786 was discontinued in February 2025 after two severe cases of elevated unconjugated bilirubin, and the stock fell 47% that day) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

It discovers and develops oral small molecule drugs aimed at G protein-coupled receptors, a receptor family involved in a very large share of human biology. Its Native Complex Platform stabilizes those receptors outside the cell so they can be screened and structurally resolved, which is the technical basis for going after targets normally addressed with injected peptides or antibodies. The company is clinical stage, meaning it is running trials and has not yet sold a drug.

Almost entirely from its global collaboration with Novo Nordisk on oral GPCR programs in obesity, type 2 diabetes and other cardiometabolic disease. Upfront and research milestone payments are recognized as revenue over time, which produced about $26.8 million in the second quarter of 2026 and roughly $99 million over the trailing year. It is partnership money, not product sales, and it stops if the underlying research programs stop.

SEPN is ordinary common stock listed on the Nasdaq, so any US broker can trade it in dollars during normal market hours, including fractionally at brokers that support fractional shares. It is also held by small-cap and biotech index funds and by actively managed healthcare funds, which is the indirect route for anyone who would rather not hold a single pre-revenue drug developer.